Tecan Group AG · SIX:TECN
Tecan — Tecan Symposium 2010
26 slides from Tecan's conference presentation, 2010
Slide 1: Applying Genomics
Applying Genomics A Rationale For Genomic Profiling in the Clinics F d i Zenhausern, Frederic Z h PhD MBA PhD., Professor & Director, ANBM Center, University of Arizona; Assoc. Dir. MDTV Division, Translational Genomics Research Institute (TGen) Di PMRL Dir. PMRL, SScottsdale tt d l Cli Clinical i l
Slide 2: Outline
Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t “Omics”, Miniaturization, Next Gen Sequencing... Toward A Precise, Intelligent, Personalized Medicine Translational Development Clinical Examples The 6th Vital Sign: Viewpoint fr
Slide 3: What is the 6th Vital Sign?
What is the 6th Vital Sign? 1. Blood pressure 2. Pulse 3. Respiration 4. Temperature 5. Pain 6. Context of Vulnerabilityy Unifying molecular diagnostics and therapeutics for a precise and personal care
Slide 4: Emergency Response Medicine
Emergency Response Medicine Who will need: •Medical M di l Triage Ti > 2 Gy? G ? • Mitigating Agent ? • Bone Marrow Transplant?
Slide 5: Medical Countermeasures Against Radiation
Medical Countermeasures Against Radiation Doctors May Risk Overuse of CT Scans November 29, 2007 U.S. not prepared for ‘dirty bomb’ attack Radiation Over‐exposure Congressional report: Nation lacks labs to test in 16 hospitals in CA for contamination after blast July, 2010 Medical scandal in France
Slide 6: Logistics for Medical Countermeasures
Logistics for Medical Countermeasures Specimen collection / identification / processing / Interpretation
Slide 7: Platform Developments Diagnostics Assays
Platform Developments Diagnostics Assays Discoveryy Test sample In Ex Ex vivo Ex vivo Control 1.5 Gy 0.5 8G y S. A. Amundson, et al. Radiat. Res. (2000)
Slide 8: 74 genes separating samples by dose
74 genes separating samples by dose Panel correctlyy predicted p p after either 6hrs or 24hrs 98% of samples Classifying of 10 samples from each dose (5 each at 6 and 24 hours after exposure) using leave one out and nearest centroid classifier Dose (G y ) Sensitivity Specificity F ive ‐dos e pre dic
Slide 9: Biomarker Performances, Classifiers
Biomarker Performances, Classifiers • Excellent E ll t – Single biomarkers ensemble classifier – Single components each competent classifiers – Clear connection with process – Simple decision by voting – Modest numbers of samples required to validate • Acceptable – Multiple biomarker aggregate class
Slide 10: Outline
Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t “Omics”, Miniaturization, Next Gen Sequencing Toward A Precise, Intelligent, Personalized Medicine Translational Development Enabling Workflow Integration and Miniaturization C
Slide 11: Workflow Integration and Miniaturization
Workflow Integration and Miniaturization 1. Sample Preparation 2. 2 DNA Quantification Q tifi ti 3. 3 DNA Amplification A lifi ti 4. 4 Detection D i 6’ 4’ 4 6’ 6 3’ 3 6’ 6 6’ 6 6’ 8’ 45’ Real‐estate for conventional Lab equipment Nanofluidics J. Gu, F. Zenhausern et al., LOC, 2007 Plastic Electronic
Slide 12: Miniaturization - Deterministic Hydrodynamic Chip
Miniaturization ‐ Deterministic Hydrodynamic Chip
Slide 13: Circulating Biomarkers – Metastatic Breast Cancer
Circulating Biomarkers – Metastatic Breast Cancer • only 27% of women diagnosed with MBC will survive to 5 years, median survival of 18 months; • Lackingg ways y to monitoringg response p to therapy py and detectingg recurrence: often relying on clinician’s experiences and bias • Current serum tumor
Slide 14: Next Gen Platforms – Grand challenge
Next Gen Platforms – Grand challenge nCP CP Fabrication F b i i off High Hi h Density D i DNA Nanoarray N for f Sequencing S i byb Hybridization H b idi i A C A C G T Stamp-2 Inking: Round 1 Gphosphoramidite Stamp-2 Printing Stamp-1 T OH T OHT Stamp-2 A C G T A C G T A C G T C G T Inking: Tphosphora
Slide 15: Printed high density nanoarrays (10 billion/cm2)
Printed high density nanoarrays (10 billion/cm2) nCP Stamp Cold welded Au array Sub‐100 nm Alignment Streptavidin protein array 100 nm size/250 nm period 5 µm
Slide 16: Multilayer Printing of Nucleoside Phosphoramidite on Nanoarray
Multilayer Printing of Nucleoside Phosphoramidite on Nanoarray
Slide 17: Personal Genomics on the Next Gen Platform
Personal Genomics on the Next Gen Platform: Genomic Data Generation/Capture SOLiD Sequencing and Genome Interrogation John Carpten Whole Genome Sequencing @ 30X Coverage; Tumor and Matched Normal DNA • Point Mutations • Indels • Translocations and Breakpoints • Copy Number • SNP Data from Drug Metab
Slide 18: Genome Sequencing Data Analysis
Genome Sequencing Data Analysis Computing time (wall‐time) per sample David Craig Whole Genome Alignment (based on corona_lite software) 400 Million 35 mer run takes 3 days 1200M reads will take ~ 9 days @ 35 mer 50 mers, ~ 15 days (20x) Ed Suh Annotation and Conversion to standard format 2‐days
Slide 19: Outline
Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t “Omics”, Miniaturization, Next Gen Sequencing Toward A Precise, Intelligent, Personalized Medicine Translational Development Clinical Examples The 6th Vital Sign: Viewpoint from
Slide 20: A Lot of People Talk About Personalized Medicine
A Lot of People Talk About Personalized Medicine 1. But who is really doing it? 2 All physicians 2. h i i try t tot practice ti personalized li d medicine • Take good care of a person 3 Let’s 3. L t’ consider id another th term t • “Precision Medicine” (because nurses and doctors already practice pe
Slide 21: Clinical Studies To Test Personalized Genomics
Clinical Studies To Test Personalized Genomics 11,935 participants i i in i 460 phase h I (first (fi in i patients) i ) trials i l new anticancer agents led to a response rate (shrink by ≥ 30%) = 4.4% Validate hypothesis that we can help patients with Refractory Advanced Cancer by profiling individu
Slide 22: Target Now (pilot trial)
Target Now (pilot trial) 1. 1 112 patients referred for phase I studies (had exhausted conventional chemotherapy options, undergoing procedures for a cancer‐related matter – e.g. obstruction) 2. Patients tissues submitted for molecular profiling in 2 formats: (i) Paraffin embedded tumor samples subm
Slide 23: Methods– Overview Mechanics
Methods– Overview Mechanics 9 national sites Selection of treatment for the patient based on MP results – via i the h following f ll i algorithm l ih • IHC/FISH and microarray indicates same target • IHC positive result alone • Microarray positive result alone
Slide 24: Results: Primary Endpoint: PFS Ratio ≥ 1.3 By Tumor Type
Results: Primary Endpoint: PFS Ratio ≥ 1.3 By Tumor Type Tumor type Total treated Number with PFS ratio≥ 1.3 (%) Breast 18 8 44 Colorectal 11 4 36 Ovarian 5 1 20 Miscellaneous* 32 5 16 66 18 27 Miscellaneous tumor types with PFS ratio ≥ 1.3 included: lung 1/3, Cholangiocarcinoma 1/2, Mesothelioma 1/
Slide 25: Conclusion
Conclusion • “Applied” Genomics is translating in clinical settings for personal care, as well as in emergency response • Multidimensional information requires combining a multitude of advanced molecular tools and sophisticated algorithms g and databases to recover intelligent g knowledge • New clin
Slide 26: Acknowledgments
Acknowledgments SCRI / Tgen Clinical Services UofA/TGen • D. von Hoff • M. Brengues M • R. Ramanathan • J. Gu • M. Bittner • J. Yangg • J. Trent • S. Rogers • R. Korn • H. Cuntliffe • M. Slater • J. Carpenten • S. Amundson (CU) We are grateful to all our sponsors, co‐workers and all the patients and